Balloon pulmonary angioplasty in chronic thromboembolic pulmonary hypertension.


Journal

Cardiovascular intervention and therapeutics
ISSN: 1868-4297
Titre abrégé: Cardiovasc Interv Ther
Pays: Japan
ID NLM: 101522043

Informations de publication

Date de publication:
Jan 2022
Historique:
received: 02 04 2021
accepted: 08 04 2021
pubmed: 1 5 2021
medline: 28 1 2022
entrez: 30 4 2021
Statut: ppublish

Résumé

Chronic thromboembolic pulmonary hypertension (CTEPH) is caused by chronic stenosis or obstruction of the pulmonary arteries due to thromboembolism. Although previous studies have shown untreated CTEPH has a poor prognosis, the establishment of gold-standard therapies including pulmonary endarterectomy, balloon pulmonary angioplasty (BPA), and medical therapy has improved hemodynamics and right ventricular function, leading to good long-term survival. BPA is an important therapy for patients with inoperable CTEPH, although the procedure is currently limited to specific institutions and operators. This review discusses the development of the rapidly evolving field of CTEPH that includes improvements in imaging modalities and advances in surgical and interventional techniques.

Identifiants

pubmed: 33928528
doi: 10.1007/s12928-021-00775-6
pii: 10.1007/s12928-021-00775-6
doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

60-65

Informations de copyright

© 2021. Japanese Association of Cardiovascular Intervention and Therapeutics.

Références

Galiè N, Humbert M, Vachiery J-L, Gibbs S, Lang I, Torbicki A, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Heart J. 2016;37:67–119.
doi: 10.1093/eurheartj/ehv317
Riedel M, Stanek V, Widimsky J, Prerovsky I. Longterm follow-up of patients with pulmonary thromboembolism. Late prognosis and evolution of hemodynamic and respiratory data. Chest. 1982;81:151–8.
doi: 10.1378/chest.81.2.151
Lang IM, Pesavento R, Bonderman D, Yuan JXJ. Risk factors and basic mechanisms of chronic thromboembolic pulmonary hypertension: a current understanding. Eur Resp J. 2013;41:462–8.
doi: 10.1183/09031936.00049312
Masahito Sakuma MN, Yamada N, Ota S, Shirato K, Nakano T, Ito M, et al. Deep vein thrombosis with pulmonary embolism, deep vein thrombosis alone, and pulmonary embolism alone. Circ J. 2009;73:305–9.
doi: 10.1253/circj.CJ-08-0372
Gall H, Hoeper MM, Richter MJ, Cacheris W, Hinzmann B, Mayer E. An epidemiological analysis of the burden of chronic thromboembolic pulmonary hypertension in the USA, Europe and Japan. Eur Respir Rev. 2017;26:160121.
doi: 10.1183/16000617.0121-2016
Poli D, Grifoni E, Antonucci E, Arcangeli C, Prisco D, Abbate R, et al. Incidence of recurrent venous thromboembolism and of chronic thromboembolic pulmonary hypertension in patients after a first episode of pulmonary embolism. J Thromb Thrombolysis. 2010;30:294–9.
doi: 10.1007/s11239-010-0452-x
Maria ABW, Kurzyna M, Dyk W, Burakowski J, Wawrzynska L, Szturmowicz M, et al. Outcome of medically versus surgically treated patients with chronic thromboembolic pulmonary hypertension. Clin Appl Thrombosis/Hemostasis. 2016;22:92–9.
doi: 10.1177/1076029614536604
Mayer E, Jenkins D, Lindner J, D’Armini A, Kloek J, Meyns B, et al. Surgical management and outcome of patients with chronic thromboembolic pulmonary hypertension: results from an international prospective registry. J Thorac Cardiovasc Surg. 2011;141:702–10.
doi: 10.1016/j.jtcvs.2010.11.024
Madani MM, Auger WR, Pretorius V, Sakakibara N, Kerr KM, Kim NH, et al. Pulmonary endarterectomy: recent changes in a single institution’s experience of more than 2,700 patients. Ann Thorac Surg. 2012;94:97–103.
doi: 10.1016/j.athoracsur.2012.04.004
Pepke-Zaba J, Delcroix M, Lang I, Mayer E, Jansa P, Ambroz D, et al. Chronic thromboembolic pulmonary hypertension (CTEPH). Circulation. 2011;124:1973–81.
doi: 10.1161/CIRCULATIONAHA.110.015008
Jeffrey A, Feinstein S, Michael JL. Balloon pulmonary angioplasty for treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2001;103:10–3.
doi: 10.1161/01.CIR.103.1.10
Kataoka M, Inami T, Hayashida K, Shimura N, Ishiguro H, Abe T, et al. Percutaneous transluminal pulmonary angioplasty for the treatment of chronic thromboembolic pulmonary hypertension. Circulation. 2012;5:756–62.
pubmed: 23132237
Mizoguchi H, Ogawa A, Munemasa M, Mikouchi H, Ito H, Matsubara H. Refined balloon pulmonary angioplasty for inoperable patients with chronic thromboembolic pulmonary hypertension. Circulation. 2012;5:748–55.
pubmed: 23192917
Kataoka M, Inami T, Kawakami T, Fukuda K, Satoh T. Balloon pulmonary angioplasty (percutaneous transluminal pulmonary angioplasty) for chronic thromboembolic pulmonary hypertension: a Japanese perspective. JACC Cardiovasc Interv. 2019;12:1382–8.
doi: 10.1016/j.jcin.2019.01.237
Reichelt A, Hoeper MM, Galanski M, Keberle M. Chronic thromboembolic pulmonary hypertension: evaluation with 64-detector row CT versus digital subtraction angiography. Eur J Radiol. 2009;71:49–54.
doi: 10.1016/j.ejrad.2008.03.016
Sugiura T, Tanabe N, Matsuura Y, Shigeta A, Kawata N, Jujo T, et al. Role of 320-slice CT imaging in the diagnostic workup of patients with chronic thromboembolic pulmonary hypertension. Chest. 2013;143:1070–7.
doi: 10.1378/chest.12-0407
Fukuda T, Ogo T, Nakanishi N, Ueda J, Sanda Y, Morita Y, et al. Evaluation of organized thrombus in distal pulmonary arteries in patients with chronic thromboembolic pulmonary hypertension using cone-beam computed tomography. Jpn J Radiol. 2016;34:423–31.
doi: 10.1007/s11604-016-0538-2
Kim NH, Delcroix M, Jais X, Madani MM, Matsubara H, Mayer E, et al. Chronic thromboembolic pulmonary hypertension. Eur Resp J. 2019;53:1801915.
doi: 10.1183/13993003.01915-2018
Kawakami T, Ogawa A, Miyaji K, Mizoguchi H, Shimokawahara H, Naito T, et al. Novel angiographic classification of each vascular lesion in chronic thromboembolic pulmonary hypertension based on selective angiogram and results of balloon pulmonary angioplasty. Circulation. 2016. https://doi.org/10.1161/CIRCINTERVENTIONS.115.003318 .
doi: 10.1161/CIRCINTERVENTIONS.115.003318 pubmed: 27729418
Takei M, Kataoka M, Kawakami T, Yamada Y, Yamada M, Fukuda K. Under-developed bronchial arteries as a risk factor for complications in balloon pulmonary angioplasty. Int J Cardiol. 2016;203:1016–7.
doi: 10.1016/j.ijcard.2015.11.104
Bogaard H, Inami T, Kataoka M, Ando M, Fukuda K, Yoshino H, et al. A new era of therapeutic strategies for chronic thromboembolic pulmonary hypertension by two different interventional therapies; pulmonary endarterectomy and percutaneous transluminal pulmonary angioplasty. PLoS ONE. 2014;9:e94587.
doi: 10.1371/journal.pone.0094587
Ogo T, Fukuda T, Tsuji A, Fukui S, Ueda J, Sanda Y, et al. Efficacy and safety of balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension guided by cone-beam computed tomography and electrocardiogram-gated area detector computed tomography. Eur J Radiol. 2017;89:270–6.
doi: 10.1016/j.ejrad.2016.12.013
Tajima H, Murata S, Kumazaki T, Abe Y, Takano T. Pulmonary artery perforation repair during thrombectomy using microcoil embolization. Cardiovasc Interv Radiol. 2005;29:155–6.
doi: 10.1007/s00270-003-0172-0
Ejiri K, Ogawa A, Matsubara H. Bail-out technique for pulmonary artery rupture with a covered stent in balloon pulmonary angioplasty for chronic thromboembolic pulmonary hypertension. JACC. 2015;8:752–3.
pubmed: 25946450
van Kan C, van der Plas MN, Reesink HJ, van Steenwijk RP, Kloek JJ, Tepaske R, et al. Hemodynamic and ventilatory responses during exercise in chronic thromboembolic disease. Jt Thorac Cardiovasc Surg. 2016;152:763–71.
doi: 10.1016/j.jtcvs.2016.05.058
Taboada D, Pepke-Zaba J, Jenkins DP, Berman M, Treacy CM, Cannon JE, et al. Outcome of pulmonary endarterectomy in symptomatic chronic thromboembolic disease. Eur Respir J. 2014;44:1635–45.
doi: 10.1183/09031936.00050114
Wiedenroth CB, Liebetrau C, Breithecker A, Guth S, Lautze H-JF, Ortmann E, et al. Combined pulmonary endarterectomy and balloon pulmonary angioplasty in patients with chronic thromboembolic pulmonary hypertension. J Heart Lung Transpl. 2016;35:591–6.
doi: 10.1016/j.healun.2015.10.030

Auteurs

Kyoko Hirakawa (K)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan. kyoko-h@kumamoto-u.ac.jp.

Eiichiro Yamamoto (E)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Seiji Takashio (S)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Shinsuke Hanatani (S)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Satoshi Araki (S)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Satoru Suzuki (S)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Koichi Kaikita (K)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Kenichi Matsushita (K)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.

Takeshi Ogo (T)

Division of Pulmonary Circulation, Department of Cardiovascular Medicine, National Cerebral and Cardiovascular Centre, Osaka, Japan.

Kenichi Tsujita (K)

Department of Cardiovascular Medicine, Faculty of Life Science, Graduate School of Medical Sciences, Kumamoto University, 1-1-1 Honjo, Kumamoto, 860-8556, Japan.
Center for Metabolic Regulation of Healthy Aging (CMHA), Kumamoto University, Kumamoto, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH